en
Scientific article
Open access
English

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma

Published inJournal of clinical oncology, vol. 30, no. 5, p. 482-487
Publication date2012
Abstract

Complete remission (CR) is uncommon during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs), but it may occur in some patients. It remains a matter of debate whether therapy should be continued after CR.

Keywords
  • Adult
  • Aged
  • Antineoplastic Agents/therapeutic use
  • Benzenesulfonates/therapeutic use
  • Carcinoma, Renal Cell/drug therapy/secondary/surgery
  • Feasibility Studies
  • Female
  • Humans
  • Indoles/therapeutic use
  • Kidney Neoplasms/drug therapy/pathology/surgery
  • Male
  • Medical Records
  • Middle Aged
  • Molecular Targeted Therapy
  • Nephrectomy
  • Niacinamide/analogs & derivatives
  • Phenylurea Compounds
  • Protein Kinase Inhibitors/therapeutic use
  • Protein-Tyrosine Kinases/antagonists & inhibitors
  • Pyridines/therapeutic use
  • Pyrroles/therapeutic use
  • Questionnaires
  • Remission Induction
  • Retrospective Studies
  • Treatment Outcome
Citation (ISO format)
ALBIGES, Laurence et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. In: Journal of clinical oncology, 2012, vol. 30, n° 5, p. 482–487. doi: 10.1200/JCO.2011.37.2516
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal0732-183X
654views
663downloads

Technical informations

Creation12/16/2014 7:38:00 AM
First validation12/16/2014 7:38:00 AM
Update time03/14/2023 10:28:19 PM
Status update03/14/2023 10:28:19 PM
Last indexation01/16/2024 3:15:41 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack